In summary, we provide evidence supporting the clinical development of the ngSERD camizestrant as monotherapy, or in double or triple combinations with CDK4/6 and AKT inhibitors, to block ER signaling more completely than currently available ETs for patients with ER+ breast cancer, and improve therapeutic outcomes. This evidence concerns the gene ESR1 and breast cancer.